SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (622)4/10/1997 8:58:00 PM
From: Brad C. Dunlap   of 1762
 
Hi Miljenko, my source of info, IDEC. True, the reasons for selling could be many from reaching their price target to financing some of the costs of clinicals, to who knows. I doubt very seriously that Smithkline figures in their budget analysis that we have plenty of money and therfore no need to budget or figure different methods of financing projects .Tuesdays filing by SmithKline of filing to sell an additional 500,000 plus shares which is probably already sold makes their selling way past 1/2 their holdings and probably closer to having very little left. As far as what is economically feasible is impossible for any outsider to speculate since no outsider has the needed info to make a logical opinion.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News